vs
EXACT SCIENCES CORP（EXAS）与富兰克林电气（FELE）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是富兰克林电气的1.8倍（$878.4M vs $500.4M），富兰克林电气净利率更高（6.9% vs -9.8%，领先16.7%），EXACT SCIENCES CORP同比增速更快（23.1% vs 9.9%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -4.0%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
富兰克林电气是全球知名的水务与能源管理产品及系统制造分销商，主营泵类、电机、驱动器及控制设备，产品广泛应用于住宅、商用、农业、工业、市政等多元场景。公司总部位于美国印第安纳州韦恩堡，在美国、德国、捷克、意大利、土耳其、墨西哥、巴西、澳大利亚、南非等多个国家设有生产基地，为全球客户提供可靠的流体运输与能源管理解决方案。
EXAS vs FELE — 直观对比
营收规模更大
EXAS
是对方的1.8倍
$500.4M
营收增速更快
EXAS
高出13.2%
9.9%
净利率更高
FELE
高出16.7%
-9.8%
两年增速更快
EXAS
近两年复合增速
-4.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $500.4M |
| 净利润 | $-86.0M | $34.7M |
| 毛利率 | 70.1% | 35.0% |
| 营业利润率 | -9.4% | 9.6% |
| 净利率 | -9.8% | 6.9% |
| 营收同比 | 23.1% | 9.9% |
| 净利润同比 | 90.1% | 10.6% |
| 每股收益（稀释后） | $-0.45 | $0.77 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFELE
| Q1 26 | — | $500.4M | ||
| Q4 25 | $878.4M | $506.9M | ||
| Q3 25 | $850.7M | $581.7M | ||
| Q2 25 | $811.1M | $587.4M | ||
| Q1 25 | $706.8M | $455.2M | ||
| Q4 24 | $713.4M | $485.7M | ||
| Q3 24 | $708.7M | $531.4M | ||
| Q2 24 | $699.3M | $543.3M |
净利润EXASFELE
| Q1 26 | — | $34.7M | ||
| Q4 25 | $-86.0M | $39.3M | ||
| Q3 25 | $-19.6M | $16.7M | ||
| Q2 25 | $-1.2M | $60.1M | ||
| Q1 25 | $-101.2M | $31.0M | ||
| Q4 24 | $-864.6M | $33.7M | ||
| Q3 24 | $-38.2M | $54.6M | ||
| Q2 24 | $-15.8M | $59.1M |
毛利率EXASFELE
| Q1 26 | — | 35.0% | ||
| Q4 25 | 70.1% | 33.8% | ||
| Q3 25 | 68.6% | 35.9% | ||
| Q2 25 | 69.3% | 36.1% | ||
| Q1 25 | 70.8% | 36.0% | ||
| Q4 24 | 69.0% | 33.8% | ||
| Q3 24 | 69.4% | 35.7% | ||
| Q2 24 | 69.8% | 36.8% |
营业利润率EXASFELE
| Q1 26 | — | 9.6% | ||
| Q4 25 | -9.4% | 10.2% | ||
| Q3 25 | -3.0% | 14.6% | ||
| Q2 25 | -0.3% | 15.0% | ||
| Q1 25 | -13.6% | 9.7% | ||
| Q4 24 | -122.8% | 8.9% | ||
| Q3 24 | -5.6% | 13.8% | ||
| Q2 24 | -3.8% | 14.6% |
净利率EXASFELE
| Q1 26 | — | 6.9% | ||
| Q4 25 | -9.8% | 7.7% | ||
| Q3 25 | -2.3% | 2.9% | ||
| Q2 25 | -0.1% | 10.2% | ||
| Q1 25 | -14.3% | 6.8% | ||
| Q4 24 | -121.2% | 6.9% | ||
| Q3 24 | -5.4% | 10.3% | ||
| Q2 24 | -2.3% | 10.9% |
每股收益（稀释后）EXASFELE
| Q1 26 | — | $0.77 | ||
| Q4 25 | $-0.45 | $0.87 | ||
| Q3 25 | $-0.10 | $0.37 | ||
| Q2 25 | $-0.01 | $1.31 | ||
| Q1 25 | $-0.54 | $0.67 | ||
| Q4 24 | $-4.69 | $0.73 | ||
| Q3 24 | $-0.21 | $1.17 | ||
| Q2 24 | $-0.09 | $1.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $80.4M |
| 总债务越低越好 | — | $134.4M |
| 股东权益账面价值 | $2.4B | $1.3B |
| 总资产 | $5.9B | $2.0B |
| 负债/权益比越低杠杆越低 | — | 0.10× |
8季度趋势，按日历期对齐
现金及短期投资EXASFELE
| Q1 26 | — | $80.4M | ||
| Q4 25 | $964.7M | $99.7M | ||
| Q3 25 | $1.0B | $102.9M | ||
| Q2 25 | $858.4M | $104.6M | ||
| Q1 25 | $786.2M | $84.0M | ||
| Q4 24 | $1.0B | $220.5M | ||
| Q3 24 | $1.0B | $106.3M | ||
| Q2 24 | $946.8M | $58.1M |
总债务EXASFELE
| Q1 26 | — | $134.4M | ||
| Q4 25 | — | $135.2M | ||
| Q3 25 | — | $135.2M | ||
| Q2 25 | — | $14.5M | ||
| Q1 25 | — | $14.9M | ||
| Q4 24 | — | $11.6M | ||
| Q3 24 | — | $11.6M | ||
| Q2 24 | — | $87.2M |
股东权益EXASFELE
| Q1 26 | — | $1.3B | ||
| Q4 25 | $2.4B | $1.3B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.5B | $1.3B | ||
| Q1 25 | $2.4B | $1.3B | ||
| Q4 24 | $2.4B | $1.3B | ||
| Q3 24 | $3.2B | $1.3B | ||
| Q2 24 | $3.2B | $1.2B |
总资产EXASFELE
| Q1 26 | — | $2.0B | ||
| Q4 25 | $5.9B | $1.9B | ||
| Q3 25 | $5.9B | $2.0B | ||
| Q2 25 | $5.8B | $2.0B | ||
| Q1 25 | $5.7B | $1.9B | ||
| Q4 24 | $5.9B | $1.8B | ||
| Q3 24 | $6.7B | $1.8B | ||
| Q2 24 | $6.7B | $1.8B |
负债/权益比EXASFELE
| Q1 26 | — | 0.10× | ||
| Q4 25 | — | 0.10× | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 0.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASFELE
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | $104.2M | ||
| Q3 25 | $219.9M | $102.7M | ||
| Q2 25 | $89.0M | $51.5M | ||
| Q1 25 | $30.8M | $-19.5M | ||
| Q4 24 | $47.1M | $110.3M | ||
| Q3 24 | $138.7M | $116.1M | ||
| Q2 24 | $107.1M | $36.4M |
自由现金流EXASFELE
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | $88.7M | ||
| Q3 25 | $190.0M | $91.3M | ||
| Q2 25 | $46.7M | $39.9M | ||
| Q1 25 | $-365.0K | $-26.3M | ||
| Q4 24 | $10.7M | $97.5M | ||
| Q3 24 | $112.6M | $106.6M | ||
| Q2 24 | $71.2M | $26.1M |
自由现金流率EXASFELE
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | 17.5% | ||
| Q3 25 | 22.3% | 15.7% | ||
| Q2 25 | 5.8% | 6.8% | ||
| Q1 25 | -0.1% | -5.8% | ||
| Q4 24 | 1.5% | 20.1% | ||
| Q3 24 | 15.9% | 20.1% | ||
| Q2 24 | 10.2% | 4.8% |
资本支出强度EXASFELE
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 3.1% | ||
| Q3 25 | 3.5% | 2.0% | ||
| Q2 25 | 5.2% | 2.0% | ||
| Q1 25 | 4.4% | 1.5% | ||
| Q4 24 | 5.1% | 2.6% | ||
| Q3 24 | 3.7% | 1.8% | ||
| Q2 24 | 5.1% | 1.9% |
现金转化率EXASFELE
| Q1 26 | — | — | ||
| Q4 25 | — | 2.65× | ||
| Q3 25 | — | 6.14× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | -0.63× | ||
| Q4 24 | — | 3.28× | ||
| Q3 24 | — | 2.13× | ||
| Q2 24 | — | 0.62× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FELE
暂无分部数据
